Research endpoints
No validated GHK-Cu monitoring panel exists. Copper-metabolism disorders are clinically important, but that does not create a universal research-product bloodwork protocol.
GHK-Cu is a copper complex, so copper homeostasis is relevant to risk interpretation.
Copper testing and interpretation belong to clinical evaluation, especially with known disorders.
Mechanistic studies do not define universal testing intervals or target ranges.
The literature supports biological activity in skin and repair models and identifies copper metabolism as a meaningful caution. It does not validate a standardized blood panel for GHK-Cu exposure.
A blood test cannot verify that a research vial contains the stated compound or is sterile. Product verification and clinical evaluation are separate questions.
